These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7563868)

  • 1. [Possibility and significance of interferon therapy for liver cirrhosis type C].
    Iwabuchi S; Osada T
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):746-53. PubMed ID: 7563868
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?].
    Harada H; Iga D; Arisaka Y; Mitsuhashi Y; Kamitsukasa H; Yagura M; Endou H; Kawashima H
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):754-8. PubMed ID: 7563870
    [No Abstract]   [Full Text] [Related]  

  • 3. [Should we treat cirrhosis in hepatitis C carriers with antiviral agents?].
    Brenard R; Closon ML; Fevery J; Hautekeete M
    Rev Med Brux; 1999 Feb; 20(1):A50. PubMed ID: 10091538
    [No Abstract]   [Full Text] [Related]  

  • 4. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liver histology as a predictor of the response to interferon therapy].
    Okuno T; Arai K; Shindo M
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):975-80. PubMed ID: 7563913
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Takemura S; Shiomi S; Kinoshita H
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hepatitis C: advances and consensus].
    Lerebours E; Marcellin P; Dhumeaux D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B5-6. PubMed ID: 12180308
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of hepatitis C virus-related cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B220-4. PubMed ID: 12180292
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The course of hepatitis C infection after liver transplantation].
    OĊ‚dakowska-Jedynak U; Paczek L
    Pol Merkur Lekarski; 2005 Aug; 19(110):220-4. PubMed ID: 16245439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
    Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvement of overexpression of endothelin B receptor in human cirrhotic liver by interferon therapy.
    Yokomori H; Oda M; Ishii H
    J Gastroenterol; 2003; 38(7):707-9. PubMed ID: 12898367
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
    Nishiguchi S; Kubo S; Shiomi S
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
    Vukotic R; Gramenzi A; Vitale G; Cursaro C; Serra C; Biselli M; Scuteri A; Andreone P; Bernardi M
    Liver Int; 2008 Mar; 28(3):407-11. PubMed ID: 17900241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimal antiviral therapy of chronic hepatitis caused by hepatitis C virus].
    Cooreman MP; Stadhouders P
    Orv Hetil; 1997 Jun; 138(22 Suppl 1):1476-82. PubMed ID: 9221377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical guidelines of diagnosis and treatment of hepatitis C].
    Rev Gastroenterol Mex; 2007; 72(2):177-91. PubMed ID: 17966381
    [No Abstract]   [Full Text] [Related]  

  • 19. [Kidney transplantation in patients positive for hepatitis C virus].
    Campistol JM; Esforzado N; Morales JM; Barrera JM
    Nefrologia; 2002; 22 Suppl 5():62-6. PubMed ID: 12107920
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatitis C: from pathogenesis to treatment].
    Delarive J; Berger JP
    Schweiz Rundsch Med Prax; 1993 Nov; 82(45):1278-83. PubMed ID: 7505477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.